Navigation Links
Empire Genomics Awarded SBIR Phase I Grant from NCI for Companion Diagnostics for Multiple Myeloma

BUFFALO, N.Y., May 28, 2013 /PRNewswire/ -- Empire Genomics, LLC ( has been awarded a Phase I SBIR Grant by the National Institute of Health/National Cancer Institute to develop a genomic companion diagnostic test for multiple myeloma (MM). This is the first SBIR grant Empire Genomics has been awarded and it will be funded through October 2013. The Company plans to use these funds to further develop its licensed technology to investigate methods in genomics to predict MM patient response to therapeutic treatments.

"Providing clinical tests that help physicians and patients better understand ideal treatments is critically important to disease management and lowering cost of healthcare," said Anthony Johnson , President & CEO of Empire Genomics. "We are excited to continue working on this assay and with pharmaceutical firms who are developing treatments for MM as we think it will be a useful resource to accelerate clinical trials and ultimately approvals."  

This SBIR funding is further validation of the Empire licensed technology, the need for companion testing in this disease area and fills a void in the early-stage funding required to develop innovative molecular diagnostics.    

About Empire Genomics

Empire Genomics LLC is a firm in the field of molecular genomic testing specializing in oncology. The company offers a wide range of best-in-class services that are used to detect genomic changes. The firm is a leader in the field of personalized medicine and helps clinicians, drug developers and researchers answer key questions in disease diagnosis, disease prognosis, and determining treatment for diseases. 


Sonya Stutts


This press release was issued through eReleases® Press Release Distribution. For more information, visit

SOURCE Empire Genomics, LLC
Copyright©2012 PR Newswire.
All rights reserved

Related biology technology :

1. Research Alert -- Empire Asset Management Co. Initiates Coverage on Exact Sciences (NASDAQ: EXAS)
2. Empire Genomics Licenses Novel DNA Biomarker for Use in Diagnosing and Creating a Companion Diagnostic Test for Neuroendocrine Prostate Cancer
3. Synthetic Genomics Inc. Hires Industry Leader George E. Stagnitti to Head Food and Nutritional Products Development Program
4. New England Biolabs Signs Agreement with Synthetic Genomics Inc. to Launch Gibson Assembly™ Master Mix for Molecular and Synthetic Biology Applications
5. Rubicon Genomics and Agendia Sign Agreement for Use of TransPLEX® Whole Genome RNA Amplification Technology With Symphony™ Cancer Diagnostics
6. Synthetic Genomics Inc. Purchases 81 Acre Site in South California Desert for Scale up and Testing of Innovative Algae Strains
7. Rosetta Genomics Pays Off Secured Loan and Reclaims Unencumbered Rights to All Assets
8. First Plant Genomics Yield Technology Progresses
9. Rosetta Genomics Announces Closing of Public Offering of 5.5 Million Ordinary Shares
10. Rosetta Genomics Receives 2012 North American Entrepreneurial Company of the Year Award by Frost & Sullivan
11. Rosetta Genomics Expands Management Team, Laboratory Capacities and Commercial Operations
Post Your Comments:
(Date:10/12/2015)... , October 12, 2015 cell surface ... billion by 2022, according to a new report by Grand ... to rise in incidence of oncology diseases and other cell-associated ... is expected to reach USD 6.49 billion by 2022, according ... growth in demand can be attributed to rise in incidence ...
(Date:10/12/2015)... CAESAREA, Israel , October 12, 2015 ... of the Dario™ Diabetes Management Solution, today announced its ... a patient case study at MobiHealth,s 5th EAI ... Focused on, "Transforming healthcare through innovations in mobile and ... London, England from October 14 - ...
(Date:10/12/2015)... ... October 12, 2015 , ... NeuMedics Inc., is a specialty ... diseases that can safely and chronically be administered as an eye drop, announced today ... by The Cleveland Clinic and taking place October 25th to October 28th at The ...
(Date:10/10/2015)... Maryland , 10. Oktober, 2015 ... Matsui (Abgeordnete der Demokratischen Partei für Kalifornien) ihre ... bis 17. Oktober) in die Aufzeichnungen des Kongresses ... Plasma Protein Therapeutics Association (PPTA) und ihren ... , Hebung des Bewusstseins über Plasmaspenden weltweit ...
Breaking Biology Technology:
(Date:9/24/2015)... , September 24, 2015 ... september 2015 Kerv ( ... finanstjänster, lanserar idag världens första kontaktlösa betalningsring ... in 77 000 GBP för massproduktion via ... ) , Kerv-bärare kan ...
(Date:9/10/2015)... -- Pursuant Health has collaborated with health experts ... image-based health risk assessment (HRA) optimized for Pursuant ... assessment quantifies user results into an easily understood ... biological age based on personal health habits, characteristics ... Comprised of age, gender, and risk ...
(Date:9/8/2015)... Sept. 8, 2015  Affectiva, global leader in ... a Service, a new data solution, and version ... on Affectiva,s highly accurate and patented science, these ... slated to transform industries such as market research, ... customer experience, online education, HR, automotive, robotics, healthcare ...
Breaking Biology News(10 mins):